Title: [The pharmacological treatment of obesity: past, present and future].
Journal: Orvosi hetilap 20120311
Title: Binding properties of antagonists to cannabinoid receptors in intact cells.
Journal: Fundamental & clinical pharmacology 20110401
Title: Cannabinoid type 1 receptor antagonists for smoking cessation.
Journal: The Cochrane database of systematic reviews 20110316
Title: Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities.
Journal: Journal of pharmacy & bioallied sciences 20110101
Title: A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet.
Journal: Obesity (Silver Spring, Md.) 20101201
Title: Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist.
Journal: The AAPS journal 20101201
Title: Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20101001
Title: In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20100901
Title: Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.
Journal: Bioorganic & medicinal chemistry letters 20100815
Title: A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study.
Journal: International journal of obesity (2005) 20100801
Title: A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes.
Journal: Diabetes, obesity & metabolism 20100601
Title: A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.
Journal: International journal of obesity (2005) 20100501
Title: Randomized, controlled, double-blind trial of taranabant for smoking cessation.
Journal: Psychopharmacology 20100401
Title: Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.
Journal: Journal of neurochemistry 20100301
Title: Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.
Journal: BMC pharmacology 20100101
Title: Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?
Journal: Cardiovascular research 20091201
Title: Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.
Journal: Journal of clinical pharmacology 20091001
Title: Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.
Journal: International journal of obesity (2005) 20090901
Title: Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
Journal: Bioorganic & medicinal chemistry letters 20090901
Title: Identification and structural elucidation of process impurities generated in the end-game synthesis of taranabant (MK-0364) via cyanuric chloride.
Journal: Journal of pharmaceutical and biomedical analysis 20090405
Title: Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
Journal: Advances in therapy 20090201
Title: Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
Journal: Journal of clinical pharmacology 20090101
Title: PET imaging studies in rhesus monkey with the cannabinoid-1 (CB1) receptor ligand [11C]CB-119.
Journal: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20090101
Title: Feeding disorders and obesity.
Journal: Current topics in behavioral neurosciences 20090101
Title: Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
Journal: Advances in therapy 20081101
Title: Taranabant, a novel cannabinoid type 1 receptor inverse agonist.
Journal: Current opinion in investigational drugs (London, England : 2000) 20081001
Title: The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Journal: Archiv der Pharmazie 20080701
Title: Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Journal: Journal of clinical pharmacology 20080601
Title: Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
Journal: Journal of medicinal chemistry 20080410
Title: Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
Journal: Journal of clinical pharmacology 20080401
Title: Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies?
Journal: Cell metabolism 20080101
Title: The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Journal: Cell metabolism 20080101
Title: The endocannabinoid system as a target for obesity treatment.
Journal: Clinical cornerstone 20080101
Title: Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Journal: The Journal of pharmacology and experimental therapeutics 20070601
Title: Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Journal: Journal of medicinal chemistry 20061228
Title: William K. Hagmann, et al. Substituted amides active at the cannabinoid-1 receptor. WO 2004048317 A1.
